NASDAQ:GOVX GeoVax Labs (GOVX) Stock Price, News & Analysis $3.64 +0.89 (+32.36%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.52 -0.12 (-3.16%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GeoVax Labs Stock (NASDAQ:GOVX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GeoVax Labs alerts:Sign Up Key Stats Today's Range$3.53▼$4.3150-Day Range$1.05▼$3.6452-Week Range$0.96▼$34.75Volume45.67 million shsAverage Volume12.06 million shsMarket Capitalization$12.63 millionP/E RatioN/ADividend YieldN/APrice Target$150.00Consensus RatingReduce Company Overview GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats. The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs. This dual approach is designed to stimulate both cellular and humoral immunity, a feature that has supported advancement of the company’s HIV vaccine candidate through Phase 2 clinical trials. GeoVax is also applying this platform to develop next-generation vaccines for hemorrhagic fever viruses and novel coronaviruses, targeting populations in regions prone to outbreaks as well as frontline health workers. Founded in 2001 and headquartered in Atlanta, Georgia, GeoVax operates in collaboration with academic institutions, government agencies and non-profit organizations. The company has received funding and technical support from the National Institutes of Health (NIH), the U.S. Department of Defense and other global health partners. These collaborations have advanced preclinical programs and facilitated clinical trial design, positioning GeoVax to rapidly respond to emerging infectious disease challenges. Leadership at GeoVax is headed by President and Chief Executive Officer James W. Bunn, who brings more than two decades of experience in biotechnology operations and clinical development. Under his direction, the management team continues to refine the company’s vaccine platform and expand its pipeline. GeoVax’s board of directors and scientific advisory board comprise experts in virology, immunology and vaccine development, guiding strategic decisions as the company advances toward late-stage clinical studies and potential licensing partnerships.AI Generated. May Contain Errors. Read More GeoVax Labs Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreGOVX MarketRank™: GeoVax Labs scored higher than 58% of companies evaluated by MarketBeat, and ranked 394th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingReduce Consensus RatingGeoVax Labs has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialGeoVax Labs has a consensus price target of $150.00, representing about 4,020.9% upside from its current price of $3.64.Amount of Analyst CoverageGeoVax Labs has only been the subject of 2 research reports in the past 90 days.Read more about GeoVax Labs' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GeoVax Labs are expected to grow in the coming year, from ($9.28) to ($4.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeoVax Labs is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeoVax Labs is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeoVax Labs has a P/B Ratio of 26.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GeoVax Labs' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.84% of the float of GeoVax Labs has been sold short.Short Interest Ratio / Days to CoverGeoVax Labs has a short interest ratio ("days to cover") of 1.97, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeoVax Labs has recently decreased by 8.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeoVax Labs does not currently pay a dividend.Dividend GrowthGeoVax Labs does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.59 News SentimentGeoVax Labs has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for GeoVax Labs this week, compared to 2 articles on an average week.Search Interest23 people have searched for GOVX on MarketBeat in the last 30 days. This is an increase of 360% compared to the previous 30 days.MarketBeat Follows4 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GeoVax Labs insiders have not sold or bought any company stock.Percentage Held by Insiders0.57% of the stock of GeoVax Labs is held by insiders.Percentage Held by Institutions6.09% of the stock of GeoVax Labs is held by institutions.Read more about GeoVax Labs' insider trading history. Receive GOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GOVX Stock News HeadlinesGeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine PlatformsMay 21 at 2:10 PM | theglobeandmail.comGeoVax Stock Higher As Company Highlights MVA Platform For Ebola ThreatsMay 20, 2026 | benzinga.comJune 4: The day smart money moves (not June 12)Everyone is watching June 12 - the SpaceX listing date. The real deadline is June 4, when Goldman Sachs, Morgan Stanley, and the largest funds begin presenting SpaceX's S-1 to clients. Buried in that filing is a small, publicly traded company that builds critical power infrastructure Musk's Colossus can't operate without. Right now it trades like a sleepy industrial stock. Dylan Jovine has the ticker and is releasing it before the roadshow begins.May 24 at 1:00 AM | Behind the Markets (Ad)GOVX stock soars 80%: Retail traders are piling in as Ebola, hantavirus risks resurfaceMay 19, 2026 | msn.comGeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq RulesMay 18, 2026 | finance.yahoo.comGeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease ThreatsMay 18, 2026 | finance.yahoo.comGeoVax Reports First Quarter 2026 Financial Results and Highlights GEO-MVA Phase 3 Trial Implementation PlansMay 15, 2026 | finance.yahoo.comGeoVax Highlights Emerging Role of Gedeptin(R) in Combination Immunotherapy Strategies Targeting Immunologically Cold TumorsMay 14, 2026 | theglobeandmail.comSee More Headlines GOVX Stock Analysis - Frequently Asked Questions How have GOVX shares performed this year? GeoVax Labs' stock was trading at $4.2750 at the start of the year. Since then, GOVX shares have decreased by 14.9% and is now trading at $3.64. How were GeoVax Labs' earnings last quarter? GeoVax Labs Inc. (NASDAQ:GOVX) released its quarterly earnings data on Wednesday, April, 15th. The company reported $1.85 earnings per share (EPS) for the quarter. When did GeoVax Labs' stock split? Shares of GeoVax Labs reverse split on Monday, January 12th 2026.The 1-25 reverse split was announced on Thursday, January 8th 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 9th 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of GeoVax Labs? Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GeoVax Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeoVax Labs investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), KALA BIO (KALA), Lipocine (LPCN), Fortress Biotech (FBIO) and Ovid Therapeutics (OVID). Company Calendar Last Earnings4/15/2026Today5/24/2026Next Earnings (Estimated)7/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 5 days ago, GOVX's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GOVX CIK832489 Webwww.geovax.com Phone(678) 384-7220Fax678-384-7281Employees10Year Founded2001Price Target and Rating Average Price Target for GeoVax Labs$150.00 High Price Target$150.00 Low Price Target$150.00 Potential Upside/Downside+4,020.9%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($19.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.47 million Net MarginsN/A Pretax Margin-2,508.10% Return on Equity-709.52% Return on Assets-399.33% Debt Debt-to-Equity RatioN/A Current Ratio1.06 Quick Ratio1.06 Sales & Book Value Annual Sales$2.49 million Price / Sales5.07 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book26.00Miscellaneous Outstanding Shares3,470,000Free Float3,453,000Market Cap$12.63 million OptionableNot Optionable Beta3.36 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:GOVX) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredThis small stock could surge when SpaceX goes publicWhen SpaceX goes public, billions in capital won't just flow into one stock - it will flood the entire sector....NXT Wave Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
